Revenio Group Corporation: Revenio Group's financial reporting and Annual General Meeting in 2020
Revenio Group Corporation, Stock Exchange Release, December 13, 2019 at 17.45
REVENIO GROUP'S FINANCIAL REPORTING AND ANNUAL GENERAL MEETING IN 2020
Revenio Group Corporation will publish the following financial reports during 2020:
- Financial Statements bulletin in regard to 2019 on Thursday, February 20, 2020
- Interim Report 1-3/2020 on Wednesday, April 22, 2020
- Interim Report 1-6/2020 on Thursday, August 6, 2020
- Interim Report 1-9/2020 on Thursday, October 22, 2020
The financial statements bulletin, half-yearly report and interim reports will be published at approximately 9 am Finnish time on the above dates.
Annual Report 2019
The Annual Report for 2019 will be published on the Group's website www.revenio.fi during week 9 in 2020. The Annual Report includes the company's Financial Statements, the Report of the Board of Directors and the Auditor's Report. At the same time, the company will publish a Corporate Governance Statement and a Remuneration Statement for 2019.
Annual General Meeting 2020
The Annual General Meeting is planned to be held on Thursday, March 20, 2019. The Board of Directors will give a separate notice of the Annual General Meeting later.
A shareholder, who wishes to place an item on the agenda of the Annual General Meeting, shall submit the request in writing to the company's Board of Directors by February 4, 2020. Such requests including the reasoning, or a resolution proposal can be submitted to the address: Revenio Group Corporation / Board of Directors, Äyritie 22, FI-01510 Vantaa, Finland.
Revenio Group Corporation
For further information, please contact:
Timo Hildén, CEO, tel. +358 40 580 4774
timo.hilden@revenio.fi
www.revenio.fi
DISTRIBUTION:
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi
The Revenio Group in brief
Revenio is a health technology company operating on the international market and a global leader in the field of ophthalmic diagnostic solutions.
The key principles of Revenio's business operations are patient-oriented screening and monitoring as well as addressing the global demand for cost-effective healthcare solutions through preventive healthcare. Revenio strives for strong growth in the health technology segment. The goal of Revenio is to develop more effective and easy-to-adopt methods for detecting illnesses with public health significance in their early stages. The goal is to improve patients’ quality of life with health technology solutions that make more efficient diagnostics possible.
Revenio specialises in the early detection and on-treatment monitoring of glaucoma, diabetic retinopathy and macular degeneration. Revenio’s Research operations, on the other hand, focus on bringing systems supporting the diagnostics and treatment planning of skin cancer and asthma to the market.
In 2018, Revenio Group’s net sales totalled EUR 30.7 million with an operating margin of 33.3%. Revenio Group Corporation is listed on Nasdaq Helsinki.